This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
=== Other interactions === SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, NSAIDs, warfarin, or other anticoagulants. Taking citalopram with omeprazole may cause higher blood levels of citalopram. This is a potentially dangerous interaction, so dosage adjustments may be needed or alternatives may be prescribed.
A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (a.k.a. shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox. Shingles provokes a painful rash with blisters and can be followed by chronic pain (postherpetic neuralgia) and other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination. Two zoster vaccines have been approved for use in people over 50 years old. Shingrix (GSK) is a recombinant subunit vaccine that has been used in many countries since 2017. Zostavax (Merck), in use since 2006, is an attenuated vaccine which consists of a larger-than-normal dose of varicella vaccine. Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system. Zostavax was discontinued in the United States in November 2020. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Varicella vaccine is used to prevent diseases caused by the same virus.
Caterpillar inflation is a method of specimen preservation found in insect collecting, used mostly during the 19th and early 20th century. As a method of preservation it has largely been replaced by freeze drying and preservation in alcohol. In some cases caterpillar inflation offers better colour retention than preservation in alcohol, although the rise of colour photography rendered this less important. A limitation of the technique was that it could produce poor results, in the form of oversized and distended specimens with poor colour, especially if carried out when the caterpillar was moulting or about to undergo pupation. Colour retention was not always perfect and some collectors painted or dyed their inflated specimens although water colours could distort the skin.
Sources: en.wikipedia.org
Premier League: 1997–98, 2001–02, 2003–04 FA Cup: 1997–98, 2001–02, 2002–03, 2004–05, 2013–14, 2014–15, 2016–17; runner-up: 2000–01 FA Charity/Community Shield: 1998, 1999, 2002, 2004, 2014, 2015 2017 Football League/EFL Cup runner-up: 2006–07, 2010–11, 2017–18 UEFA Champions League runner-up: 2005–06 UEFA Cup runner-up: 1999–2000 Individual
This myth originated from a misinterpreted joke in a 2013 report of a pacu being found in Øresund, the strait between Sweden and Denmark, which claimed that the fish ate "nuts". Piranhas do not eat only meat but are omnivorous, and they swim in schools only to defend themselves from predators and not to attack. They very rarely attack humans, only when under stress and feeling threatened, and even then, bites typically only occur on hands and feet. Sharks can get cancer. The misconception that sharks do not get cancer was spread by the 1992 book Sharks Don't Get Cancer, which was used to sell extracts of shark cartilage as cancer prevention treatments. Reports of carcinomas in sharks exist, and current data does not support any conclusions about the incidence of tumors in sharks. Great white sharks do not mistake human divers for seals or other pinnipeds. When attacking pinnipeds, the shark surfaces quickly and attacks violently. In contrast, attacks on humans are slower and less violent: the shark charges at a normal pace, bites, and swims off. Great white sharks have efficient eyesight and color vision; the bite is not predatory, but rather for identification of an unfamiliar object. Snake jaws cannot unhinge. The posterior end of the lower jaw bones contains a quadrate bone, allowing jaw extension. The anterior tips of the lower jaw bones are joined by a flexible ligament allowing them to bow outwards, increasing the mouth gape. Snakes are not deaf or only able to sense ground vibrations.
Breó (meaning 'glow' in Irish) was a wheat beer; it cost around IR£5 million to develop. A brewing byproduct of Guinness, Guinness Yeast Extract (GYE), was produced until the 1950s. In the UK, a HP Guinness Sauce was manufactured by Heinz and available as of 2013. In March 2010, Guinness began test marketing Guinness Black Lager, a new black lager, in Northern Ireland and Malaysia. As of September 2010, Guinness Black Lager is no longer readily available in Malaysia. In October 2010, Guinness began selling Foreign Extra Stout in 4 packs of bottles in the United States.
Gordon Freeman, PhD, is the silent protagonist of the Half-Life series and the playable character in Half-Life and all games in the Half-Life 2 series. He is a theoretical physicist and holds a PhD from MIT in that field. At the time of Half-Life, he works at Black Mesa Research Facility, a facility in New Mexico, conducting nuclear and subatomic research. After being at ground zero during the "resonance cascade", Gordon fights his way through Black Mesa and eventually reaches the Lambda Complex where a group of surviving scientists are getting ready to teleport him to Xen in order for Gordon to kill a large entity (The "Nihilanth") holding the portals open in Xen. In doing so he frees the alien race of vortigaunts from slavery and is hired by the G-Man for an unknown future job. In Half-Life 2 he is re-awoken from stasis by the G-man and meets up with the resistance on Earth against the Combine. The resistance view him as a very important figure due to the mythos surrounding what he did in Black Mesa. He eventually becomes one of the leading figures in the resistance, almost single-handedly destroying the Combine prison, Nova Prospekt, and signaling the uprising to begin. During the uprising, Gordon fights his way through the ruined streets of City 17 and enters the Citadel. He and Alyx Vance attempt to stop Dr. Wallace Breen from teleporting to a Combine Planet and blow up the teleporter he was trying to use.
Sources: en.wikipedia.org
The National Democrats did not want to assume the lands they considered politically undesirable, as such territorial enlargement would result in a reduced proportion of citizens who were ethnically Polish.
The etched structure of silver nanoparticles provides the chloride with the preferred atomic steps for nucleation to occur.Reaction of Silver with Chloride:Ag+ + Cl− → AgClAgCl(s) + Cl−(aq) → AgCl2−(aq) Ag has also been shown to readily react with sulfur in water. Free Ag+ ions will react with H2S in the water to form the precipitate Ag2S. Silver and Sulfur Reaction in Seawater:2Ag(aq) + H2S(aq) → Ag2S(s) + H2(aq) H2S is not the only source of sulfur that Ag will readily bind to. Organosulfur compounds, which are produced by aquatic organisms, form extremely stable sulfide complexes with silver. Silver outcompetes other metals for the available sulfide, leading to an overall decrease in bioavailable sulfur in the community. Thus, the formation of Ag2S limits the amount of bioavailable sulfur and contributes to a reduction in toxicity of silver nanoparticles to nitrifying bacteria.
== Future == Rönnberg has stated there will not be a sequel to Cry of Fear, as he considers the story completed. A remake was in development by Team Psykskallar, but production time and cost surpassed the original game and the project was abandoned. In August 2023, Rönnberg revealed he has been planning a new horror game, similar to both Afraid of Monsters and Cry of Fear, and the game was currently in the early writing phase.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.